Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (212)	7/6/1998 4:15:00 PM
From: GREG FINLEY	Read Replies (1) \| Respond to of 534

James, Marc, & all, First, thanks Marc for your work and passing the info on. I hope that the info proves helpful to all who visit the sites you made available. Second, I also believe that the sales shift will prove to be fruitful as I mentioned here and in the quote.yahoo.com forum. Yes, the price does seem to be holding despite a constant supply of sell orders (although some of them seem to be quite small and are probably people who are tired of waiting!) As for myself, I'll just sit back and wait for news to send this stock up (and while I do, recite my new mantra "all good things come to those who wait"! It's gonna happen! GREG

To: James Strauss who wrote (212)	7/21/1998 8:31:00 PM
From: Marc Kahn	Read Replies (3) \| Respond to of 534

I heard an interesting tid-bit today. This falls under the "rumor" category, but considering where it came from, I believe that it is true. Apparently the sales rep devoted to pursuing the US military is doing a good job. Bioject has received an order for more than 100,000 Biojector ampules for the military. We are currently in the 2nd quarter, which has historically been our best quarter for product sales, because of flu shot season. With additional orders such as this one, we could be headed for a very good "revenue from product sales" number for Q2. Add in the $1.5 million up-front payment from Merck, and I don't think a person would be too far out of line predicting a PROFITABLE quarter. Wouldn't that feel good? Marc Kahn